GO
Loading...

Amgen Inc

More

  • Early Glance: Biotechnology companies Wednesday, 23 Apr 2014 | 10:29 AM ET

    Amgen Inc. fell $5.56 or 4.7 percent, to $113.74. Biogen Idec fell $5.05 or 1.6 percent, to $301.16. Celgene Corp. fell$. 18 or. 1 percent, to $146.46.

  • US STOCKS-Wall St edges lower following six-day S&P rally Wednesday, 23 Apr 2014 | 10:17 AM ET

    *Boeing rallies after results, outlook; AT&T drops. NEW YORK, April 23- U.S. stocks edged lower on Wednesday as strong results from Boeing failed to inspire investors to keep pushing equities higher following six straight days of gains.

  • April 22- Amgen Inc on Tuesday reported lower-than-expected first quarter profit as sales of several key products fell short of Wall Street estimates, with its big-selling rheumatoid arthritis drug Enbrel particularly hard hit by inventory stocking by wholesalers late last year.

  • Amgen misses 1Q views as higher costs cut profit Tuesday, 22 Apr 2014 | 4:39 PM ET

    Despite higher sales, biotech drugmaker Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply. The maker of injected osteoporosis treatment Prolia said Tuesday that net income was $1.07 billion, or $1.40 per share, down from $1.43 billion, or $1.88 per share, in 2013' s first quarter.

  • April 22- Amgen Inc on Tuesday reported lower-than-expected first quarter profit as results were hurt by acquisition-related costs as well as sales of several key products that fell short of Wall Street estimates.

  • AstraZeneca cancer pipeline likely draw for Pfizer Monday, 21 Apr 2014 | 6:16 PM ET
    A Pfizer technician as she works at Neusentis Ltd.'s research laboratory, a unit of Pfizer Inc., in Cambridge, U.K., on Thursday, Sept. 26, 2013.

    Pfizer Inc may come back to bid for British drug company AstraZeneca Plc after its reported 60 billion pound takeover approach was rejected.

  • Final Glance: Biotechnology companies Monday, 21 Apr 2014 | 6:02 PM ET

    Amgen Inc. rose $1.56 or 1.4 percent, to $117.02. Biogen Idec rose $7.44 or 2.6 percent, to $297.98. Celgene Corp. rose $2.32 or 1.6 percent, to $143.83.

  • Midday Glance: Biotechnology companies Monday, 21 Apr 2014 | 1:20 PM ET

    Amgen Inc. rose$. 89 or. 8 percent, to $116.35. Biogen Idec rose $3.44 or 1.2 percent, to $293.98. Celgene Corp. rose $1.03 or. 7 percent, to $142.54.

  • Early Glance: Biotechnology companies Monday, 21 Apr 2014 | 10:31 AM ET

    Amgen Inc. rose$. 91 or. 8 percent, to $116.37. Biogen Idec rose $3.58 or 1.2 percent, to $294.12. Celgene Corp. rose $1.63 or 1.2 percent, to $143.14.

  • AstraZeneca cancer pipeline seen as draw for Pfizer Monday, 21 Apr 2014 | 6:55 AM ET

    LONDON, April 21- Pfizer may come back to bid for British drug company AstraZeneca after its reported 60 billion pound takeover approach was rejected, since a deal could make sense for the U.S. pharmaceuticals giant as it seeks to build up its cancer franchise.

  • Final Glance: Biotechnology companies Wednesday, 16 Apr 2014 | 6:02 PM ET

    Amgen Inc. rose$. 54 or. 5 percent, to $115.54. Biogen Idec rose $5.99 or 2.1 percent, to $291.48. Celgene Corp. rose $2.02 or 1.4 percent, to $141.86.

  • Midday Glance: Biotechnology companies Wednesday, 16 Apr 2014 | 1:30 PM ET

    Amgen Inc. rose$. 17 or. 1 percent, to $115.17. Biogen Idec rose $5.59 or 2.0 percent, to $291.08. Celgene Corp. rose $1.52 or 1.1 percent, to $141.36.

  • Early Glance: Biotechnology companies Wednesday, 16 Apr 2014 | 10:27 AM ET

    Amgen Inc. fell$. 34 or. 3 percent, to $114.67. Biogen Idec rose $2.08 or. 7 percent, to $287.57. Celgene Corp. rose $1.35 or 1.0 percent, to $141.19.

  • NEW YORK, April 16- Predicting when the bear market in biotech stocks will hit bottom is a hazardous prospect, but one gauge that factors in the rapid profit growth estimates for many of these companies suggests several are starting to look attractive.

  • Trader on the floor of the New York Stock Exchange.

    The Nasdaq staged a more than 2 percent rally back from the brink of correction territory Tuesday in the biggest one day turnaround in five years.

  • Final Glance: Biotechnology companies Monday, 14 Apr 2014 | 6:01 PM ET

    Amgen Inc. rose $1.38 or 1.2 percent, to $113.32. Biogen Idec rose $5.52 or 2.0 percent, to $279.52. Celgene Corp. rose $1.16 or. 8 percent, to $138.06.

  • Midday Glance: Biotechnology companies Monday, 14 Apr 2014 | 2:08 PM ET

    Amgen Inc. rose $2.12 or 1.9 percent, to $114.06. Biogen Idec rose $6.40 or 2.3 percent, to $280.40. Celgene Corp. rose $1.64 or 1.2 percent, to $138.54.

  • Buffett likes papers, and I do too: 5-star manager Monday, 14 Apr 2014 | 11:03 AM ET

    This media company has "Warren Buffett's kind of community newspapers," said Smead Capital Management's Bill Smead, who also likes an insurer and a biotech company.

  • Early Glance: Biotechnology companies Monday, 14 Apr 2014 | 10:21 AM ET

    Amgen Inc. rose$. 01 or percent, to $111.95. Biogen Idec rose $3.06 or 1.1 percent, to $277.06. Celgene Corp. rose $1.60 or 1.2 percent, to $138.50.

  • Final Glance: Biotechnology companies Friday, 11 Apr 2014 | 6:02 PM ET

    Amgen Inc. fell $2.17 or 1.9 percent, to $111.94. Biogen Idec fell $13.35 or 4.6 percent, to $274.00. Celgene Corp. fell $3.08 or 2.2 percent, to $136.90.

Most Popular Video

Wednesday, 23 Apr 2014 | 7:33 AM ET

J. Michael Pearson, Valeant Pharmaceuticals chairman & CEO, explains why he decided to pursue Allergan and shares his R&D business model, with CNBC's Kate Kelly. This year we are launching 19 products in the United States, says Pearson.

Wednesday, 23 Apr 2014 | 6:13 AM ET

Chris Caso, Susquehanna Financial Group analyst, shares his outlook on Apple in the second half. Apple needs to show shareholders the next new thing, says Caso.

Wednesday, 23 Apr 2014 | 4:10 AM ET

Fraser Howie, director at Newedge Singapore, says the PMI data reveals China is "in a bit of a rut" and that the government has a "horrible problem" as it can't bring out too much stimulus.